↓ Skip to main content

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Overview of attention for article published in Diabetologia, October 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

policy
1 policy source
twitter
16 tweeters

Citations

dimensions_citation
126 Dimensions

Readers on

mendeley
95 Mendeley
Title
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Published in
Diabetologia, October 2016
DOI 10.1007/s00125-016-4134-x
Pubmed ID
Authors

Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst, Jan W. T. Fiolet, Ger J. M. Stienen, Ruben Coronel, Coert J. Zuurbier

Abstract

Empagliflozin (EMPA), an inhibitor of the renal sodium-glucose cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 diabetes. The underlying mechanism of this effect is unknown. Elevated cardiac cytoplasmic Na(+) ([Na(+)]c) and Ca(2+) ([Ca(2+)]c) concentrations and decreased mitochondrial Ca(2+) concentration ([Ca(2+)]m) are drivers of heart failure and cardiac death. We therefore hypothesised that EMPA would directly modify [Na(+)]c, [Ca(2+)]c and [Ca(2+)]m in cardiomyocytes. [Na(+)]c, [Ca(2+)]c, [Ca (2+)]m and Na(+)/H(+) exchanger (NHE) activity were measured fluorometrically in isolated ventricular myocytes from rabbits and rats. An increase in extracellular glucose, from 5.5 mmol/l to 11 mmol/l, resulted in increased [Na(+)]c and [Ca(2+)]c levels. EMPA treatment directly inhibited NHE flux, caused a reduction in [Na(+)]c and [Ca(2+)]c and increased [Ca(2+)]m. After pretreatment with the NHE inhibitor, Cariporide, these effects of EMPA were strongly reduced. EMPA also affected [Na(+)]c and NHE flux in the absence of extracellular glucose. The glucose lowering kidney-targeted agent, EMPA, demonstrates direct cardiac effects by lowering myocardial [Na(+)]c and [Ca(2+)]c and enhancing [Ca(2+)]m, through impairment of myocardial NHE flux, independent of SGLT2 activity.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 95 100%

Demographic breakdown

Readers by professional status Count As %
Other 13 14%
Researcher 12 13%
Student > Ph. D. Student 11 12%
Student > Bachelor 9 9%
Student > Master 8 8%
Other 25 26%
Unknown 17 18%
Readers by discipline Count As %
Medicine and Dentistry 50 53%
Biochemistry, Genetics and Molecular Biology 8 8%
Agricultural and Biological Sciences 5 5%
Unspecified 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 5 5%
Unknown 22 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2018.
All research outputs
#1,324,505
of 14,045,330 outputs
Outputs from Diabetologia
#744
of 3,950 outputs
Outputs of similar age
#41,499
of 290,560 outputs
Outputs of similar age from Diabetologia
#29
of 80 outputs
Altmetric has tracked 14,045,330 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,950 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.5. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.